GlassScriptPhysician profile
Joe Taylor
NPI 1851347215
$38,018.22
in general payments reported to CMS, 2019-2025
25 companies · $8,734 in 2025
The $8,734 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,065 · 2022: $8,761 · 2023: $8,543 · 2024: $4,915 · 2025: $8,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $3,402 · Travel and Lodging: $218 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,500.00 |
| Food and Beverage | $3,402.20 |
| Travel and Lodging | $218.21 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34,255.26 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $576.68 | 2021-2025 | Caplyta |
| Alkermes, INC. | $360.25 | 2021-2023 | Lybalvi, Aristada, Vivitrol |
| Vanda Pharmaceuticals INC. | $353.60 | 2021-2025 | Fanapt, Hetlioz |
| Astrazeneca Pharmaceuticals LP | $338.02 | 2024-2025 | Farxiga, Airsupra, Lokelma |
| Neurocrine Biosciences, INC. | $301.26 | 2021-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $289.65 | 2021-2023 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $208.28 | 2022-2024 | Invega, Spravato |
| Otsuka America Pharmaceutical, INC. | $201.63 | 2021-2025 | Rexulti, Abilify Maintena |
| Indivior INC. | $163.12 | 2022-2025 | Perseris, Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $158.13 | 2021-2022 | |
| Lundbeck LLC | $155.13 | 2024-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $128.61 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2024 | Dupixent |
| Corium, LLC | $80.09 | 2021-2025 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $79.65 | 2024-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $65.32 | 2022 | |
| Lilly USA, LLC | $54.09 | 2024-2025 | Mounjaro, Zepbound |
| Csl Behring | $22.54 | 2025 | Andembry |
| Jazz Pharmaceuticals INC. | $22.14 | 2021 | |
| Philips North America LLC | $20.05 | 2024 | (Ck7) Extended Holter |
| Scilex Pharmaceuticals INC. | $18.15 | 2023 | Ztlido |
| Boston Scientific Corporation | $15.33 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.27 | 2024 | Nuzyra |
| Ironshore Pharmaceuticals INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.